Design of a prodrug bispecific antibody masked by a functional molecule for lymphocyte activation for cancer therapy
Abstract Although T cells engaging bispecific antibodies (T-bsAbs) have shown great benefits, their use in treating solid tumors is challenging because of the minimal infiltration of T-cells. We fused an agonistic single-chain variable fragment (scFv) that induces a T cell co-stimulatory signal to t...
Saved in:
| Main Authors: | Daimei Miura, Yuki Kato, Masahiro Yasunaga, Izumi Kumagai, Ryutaro Asano |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Journal of Biological Engineering |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13036-025-00517-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
by: Zhijuan Ai, et al.
Published: (2025-01-01) -
Immunological synapse formation as a key mechanism in T cell-dependent bispecific antibody-mediated immune activation and cytotoxicity
by: Rikuto Nakamura, et al.
Published: (2025-06-01) -
A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs
by: Itzel Condado-Morales, et al.
Published: (2024-12-01) -
Current Trends in Clinical Trials of Prodrugs
by: Diogo Boreski, et al.
Published: (2025-02-01) -
Preparation of Glutathione-Responsive Paclitaxel Prodrug Based on Endogenous Molecule of L-Glutathione Oxidized for Cancer Therapy
by: Xiao Duan, et al.
Published: (2024-09-01)